Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06428045 · ClinicalTrials.gov registry record · Phase 1

STARLITE for Unresectable High-Grade Gliomas

A Phase 1 study of High Grade Glioma, sponsored by University of Miami.

Recruiting
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT06428045: Recruiting Phase 1 study of High Grade Glioma, sponsored by University of Miami.

NCT06428045 is a Phase 1 study of High Grade Glioma that is actively recruiting participants, run by University of Miami. The registered enrollment target is 24 participants, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06428045, a Phase 1 study of High Grade Glioma, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed surgically change as a result of the study treatment; and to identify and evaluate the potential side effects (good and bad) of the study treatment in patients with newly diagnosed high-grade glioma(s) that cannot be removed surgically.

Primary Outcome

The number of participants experiencing dose-limiting toxicity (DLT) during the first 28 days of antiretroviral therapy (ART) will be reported. Toxicity will be assessed by the treating physician and assigned severity and attribution using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0).

Conditions Studied

Interventions

  • DRUG Temozolomide
  • PROCEDURE Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT)
  • DRUG Abacavir
  • DRUG Lamivudine
  • DRUG Ritonavir

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-04-15
Est. Completion 2030-04-30
Phase Phase 1
University of Miami

721 total trials

What NCT06428045 shows while recruiting

NCT06428045 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (63% lower).

The record links to 1 condition, with High Grade Glioma appearing as the primary indexed condition, and to 5 interventions - of which Temozolomide is the first listed.

NCT06428045 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06428045 about?

NCT06428045 is a clinical study titled "STARLITE for Unresectable High-Grade Gliomas". The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed surgically change as a result of the study treatment; and to identify and evaluate the potential side effects (good and bad) of the study treatment in patients with newly diagnosed high-grad...

What is the current status of trial NCT06428045?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-04-15. Estimated completion is 2030-04-30.

What conditions does trial NCT06428045 study?

This clinical trial studies the following conditions: High Grade Glioma.

What interventions are being tested in trial NCT06428045?

The interventions under investigation include: Temozolomide (DRUG), Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT) (PROCEDURE), Abacavir (DRUG), Lamivudine (DRUG), Ritonavir (DRUG).

Who is sponsoring clinical trial NCT06428045?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06428045 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for High Grade Glioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06428045's enrollment target sits among peer trials

24 29th of 42 higher than 14 of 42 other High Grade Glioma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other High Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06428045, the US trial registry maintained by the National Library of Medicine. NCT06428045 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.